Biogen’s experimental drug for Alzheimer’s disease failed

Source Reference

Biogen’s experimental drug called aducanumab failed to help patients with Alzheimer’s disease. The hypothesis was that too much beta amyloid in the brain impacts the progress of the disease.

Indeed, one biotech analyst said that this result will be considered among the biggest failures in biopharma memory. The evidence was mostly weak about the potential treatment for this disease. However, the company insists that previous failures helped move their research forward.

Actually, Biogen’s core products are medications for multiple sclerosis, which has been proven to be treated with stem cell therapy. Besides, there are other drugs from other companies that have also failed to improve the condition of patients with this disease.

For example, Pfizer has decided to stop research on the beta amyloid hypothesis as well as Parkinson’s disease.

Moreover, Alzheimer’s disease impacts 5 million in the US and tens of millions worldwide. There are many clinical trials ongoing using stem cell therapy.

Despite the obstacles for medical practitioners and the patients they seek to serve, the FDA did approve stem cell therapy for arthritis and neuropathy. Besides, there are more than 200 clinical trials that you can find on clinicaltrials.org at this moment. Furthermore, there is research and data from many other clinical trials that prove the safety and efficacy of this therapy.